Clinical Trial Update: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on combining acalabrutinib (ACP-196) with ACP-319 for B-cell malignancies, including non-Hodgkin lymphoma, multiple myeloma, and B-cell ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• ACP-319 (ACP-319)
• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Non-Hodgkins Lymphoma, Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-30